VHT vs IBB.
Vanguard Health Care ETF (MSCI US IMI Health Care 25/50) against iShares Biotechnology ETF (NYSE Biotechnology) — fees, long-horizon total returns, holdings overlap, and sector tilt, side by side.
Daily bar history for this pair isn’t loaded yet — returns will appear once the nightly ingest covers both funds.
| VHT | IBB | |
|---|---|---|
| Name | Vanguard Health Care Index Fund ETF Shares | iShares Biotechnology ETF |
| Category | Health | Health |
| Style | Passive | Passive |
| Expense ratio | 0.09% | 0.45% |
| Assets (AUM) | $20.4B | $9.1B |
| Dividend yield | 1.58% | 0.22% |
| Avg volume (3-mo) | 253K | 1.6M |
| Inception | January 26, 2004 | February 5, 2001 |
| Benchmark proxy | S&P 500 | S&P 500 |
VHT costs 0.36 pp less per year — about $36.00 per $10,000 invested.
Expense ratios verified against issuer fact sheets. Dividend yield is trailing 12-month distributions divided by price, as reported by the fund data provider.
| Shared holding | VHT | IBB | MIN |
|---|---|---|---|
| AMGNAmgen Inc | 2.87% | 7.82% | 2.87% |
| GILDGilead Sciences Inc | 2.31% | 6.83% | 2.31% |
Sum of min(weight in each fund) across shared tickers — the standard fund-overlap measure. Computed on the top 25 holdings each fund reports, so it is a lower bound; the coverage figures show how much of each fund those top holdings represent.